Tarsus Pharmaceuticals, Inc. (TARS) › Cash & EquivalentsTarsus Pharmaceuticals, Inc. (TARS) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $57.95M2020: $168.13M2021: $171.33M2022: $71.66M2023: $224.95M2024: $94.82M2025: $183.64M$183.64M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$183.64M+93.7%2024$94.82M-57.8%2023$224.95M+213.9%2022$71.66M-58.2%2021$171.33M+1.9%2020$168.13M+190.1%2019$57.95M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share